Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | METAP1 | P53582 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5367329 | 0.75 | METAP1 (0.35) | CYP1A2CYP3A4METAP1 | |
| SCHEMBL5379956 | 0.74 | CYP1A2 (0.48) | CYP1A2CYP3A4METAP1 | |
| SCHEMBL4047356 | 0.74 | CYP1A2 (0.48) | CYP1A2CYP3A4METAP1 | |
| SCHEMBL4047359 | 0.74 | CYP1A2 (0.48) | CYP1A2CYP3A4METAP1 | |
| SCHEMBL5367334 | 0.72 | METAP1 (0.35) | METAP1 | |
| SCHEMBL14559785 | 0.68 | CYP1A2 (0.48) | CYP1A2CYP3A4METAP1 | |
| SCHEMBL14559784 | 0.68 | CYP1A2 (0.48) | CYP1A2CYP3A4METAP1 | |
| SCHEMBL13004316 | 0.65 | CYP1A2 (0.39) | CYP1A2CYP3A4METAP1 | |
| SCHEMBL2947951 | 0.65 | CYP1A2 (0.45) | CYP1A2CYP3A4METAP1 | |
| SCHEMBL2946324 | 0.65 | CYP1A2 (0.45) | CYP1A2CYP3A4METAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1673377-B1 | PROCESS FOR THE PREPARATION OF 3-AMINO-2-HYDROXYPROPYLPHOSPHINIC ACID DERIVATIVES | AVENTIS PHARMA INC (US) | 2013-12-25 | — | — | EP | disclosed |
| US-7186705-B2 | Process for the preparation of 3-amino-2-hydroxypropylphosphinic acid derivatives | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-06 | — | — | US | disclosed |
| EP-1673377-A1 | PROCESS FOR THE PREPARATION OF 3-AMINO-2-HYDROXYPROPYLPHOSPHINIC ACID DERIVATIVES | Aventis Pharmaceuticals Inc. (US) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005030781-A1 | PROCESS FOR THE PREPARATION OF 3-AMINO-2-HYDROXYPROPYLPHOSPHINIC ACID DERIVATIVES | AVENTIS PHARMACEUTICALS INC. (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20050070507-A1 | Process for the preparation of 3-amino-2-hydroxypropylphosphinic acid derivatives | AVENTIS PHARMACEUTICALS INC. (US) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070507-A1 | Process for the preparation of 3-amino-2-hydroxypropylphosphinic acid derivatives | HTR5A, HPD, HNMT | CYP1A2 559/4885CYP3A4 825/4885METAP1 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.